

Debra L Richardson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4307417/publications.pdf>

Version: 2024-02-01

43
papers

1,948
citations

471061

17
h-index

329751

37
g-index

44
all docs

44
docs citations

44
times ranked

2800
citing authors

#	ARTICLE	IF	CITATIONS
1	The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. <i>Gynecologic Oncology</i> , 2009, 112, 55-59.	0.6	597
2	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. <i>Gynecologic Oncology</i> , 2015, 136, 3-7.	0.6	246
3	A detailed analysis of the learning curve: Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 162-167.	0.6	144
4	Robotic Hysterectomy and Pelvicâ€Aortic Lymphadenectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2008, 112, 1207-1213.	1.2	116
5	Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 667-672.	0.6	97
6	Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2009, 113, 11-17.	1.2	83
7	A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 464-471.	0.4	66
8	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 196.	3.4	60
9	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 111, 461-466.	0.6	52
10	Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , 2016, 127, 468-473.	1.2	50
11	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (ReolysinÂ®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 477-483.	0.6	50
12	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	0.6	49
13	Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?. <i>Gynecologic Oncology</i> , 2010, 118, 47-51.	0.6	39
14	Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 396-400.	0.6	37
15	Malignant ovarian germ cell tumor â€” Role of surgical staging and gonadal dysgenesis. <i>Gynecologic Oncology</i> , 2014, 134, 84-89.	0.6	33
16	Ovarian involvement in endometrioid adenocarcinoma of uterus. <i>Gynecologic Oncology</i> , 2015, 138, 532-535.	0.6	32
17	Paratubal borderline serous tumors. <i>Gynecologic Oncology</i> , 2009, 113, 83-85.	0.6	22
18	Local correction of extreme stomal prolapse following transverse loop colostomy. <i>Gynecologic Oncology</i> , 2008, 111, 549-551.	0.6	17

#	ARTICLE	IF	CITATIONS
19	The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 223, 108-112.	0.5	15
20	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncologyâ€™s Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	1.9	15
21	Robotic hysterectomy and lymphadenectomy for endometrial cancer: technical aspects and details of successâ€™the Ohio State University method. <i>Journal of Robotic Surgery</i> , 2008, 2, 71-76.	1.0	14
22	Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. <i>Gynecologic Oncology</i> , 2012, 127, 43-46.	0.6	14
23	CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2008, 111, 233-236.	0.6	13
24	Robotic Pelvic and Aortic Lymphadenectomy for Endometrial Cancer: The Console Surgeon's Perspectives on Surgical Technique and Directing the Assistant. <i>Journal of Minimally Invasive Gynecology</i> , 2010, 17, 180-185.	0.3	12
25	The prognostic significance of the triple negative phenotype in endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 118, 172-175.	0.6	11
26	Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 131-155.	0.6	9
27	Outpatient Platinum-Taxane Intraperitoneal Chemotherapy Regimen for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1195-1198.	1.2	9
28	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	1.2	7
29	Factors associated with clinical trial screening failures in gynecologic oncology. <i>Gynecologic Oncology</i> , 2014, 134, 450-454.	0.6	7
30	Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2008, 108, 449-451.	0.6	6
31	Metastatic Squamous Cell Carcinoma of the Vulva to the Lung Confirmed With Allelotyping. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 497-501.	0.9	6
32	Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer That Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1125-1131.	1.2	6
33	Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. <i>Gynecologic Oncology</i> , 2012, 124, 508-511.	0.6	4
34	Adnexal masses requiring surgical intervention in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , 2014, 134, 552-555.	0.6	4
35	Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. <i>Gynecologic Oncology</i> , 2009, 115, 306-307.	0.6	2
36	Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. <i>Brachytherapy</i> , 2016, 15, 341-346.	0.2	1

#	ARTICLE	IF	CITATIONS
37	What is the real risk for trisomy 18?. American Journal of Obstetrics and Gynecology, 2003, 189, S233.	0.7	0
38	RE: Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecologic Oncology, 2008, 110, 269.	0.6	0
39	Corrigendum to "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer" [Gynecologic Oncology 111 (2008) 461-466]. Gynecologic Oncology, 2010, 119, 603.	0.6	0
40	Malignant Uterine Perivascular Epithelioid Cell Tumor: A Case Report. Clinical Ovarian and Other Gynecologic Cancer, 2012, 5, 37-39.	0.1	0
41	Isolated ovarian metastasis in endometrial adenocarcinoma of uterus. Gynecologic Oncology, 2014, 135, 393.	0.6	0
42	Factors influencing primary treatment of midline vulvar cancers. Gynecologic Oncology, 2016, 142, 133-138.	0.6	0
43	Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, e15501-e15501.	0.8	0